Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs... Read more

Stock Quote

PTGX (Common Stock)
$15.17 + 0.08 (0.00%)
Exchange :NASDAQ
Volume :83,968
Today's Open$15.18
Previous Close$15.17
Data as of February 17, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $15.17 with a 52 week high of $26.36 and a 52 week low of $10.02.

Recent Press Releases

February 01, 2017

Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference read more

January 17, 2017

Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis read more

January 05, 2017

Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100 read more

Upcoming Events

There are currently no events scheduled.


Corporate Presentation January 2017

Data provided by Nasdaq. Minimum 15 minutes delayed.